Market News How it works Learn FAQ
| RCT 0.084 10.38% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2377 7.31% | AZTR 1.51 111.19% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SOXL 90.5 8.31% | INTC 90.47 4.04% | SHFS 0.094 -29.00% | VALE 12 -3.23% | NVDA 216.019 2.40% | CLRO 4.97 52.92% | NOK 8.64 6.14% | TSLL 10.76 10.25% | JBLU 2.37 -9.71% | CRWV 55.19 1.76% | GCDT 0.1497 -14.99% | SOXS 47.98 -8.54% | ABEV 2.83 -14.24% | NWGL 0.0857 4.51% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | RIG 6.53 1.87% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | SID 0.9118 -22.73% | RBNE 0.1671 -12.05% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | PLUG 1.37 -0.72%
TLTriSalus Life Sciences, Inc. logo

TriSalus Life Sciences, Inc. (TLSI)

NASDAQ Global Market · Currency in USD
$3.62 ▲ +0.03 (+0.84%)
At close: Oct 26, 4:00 PM ET. Market closed.
$3.62 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:01 PM ET

Summary

Previous Close
$3.59
Open
$3.66
Day's Range
$3.59 – $3.68
52 Week Range
$2.20 – $7.95
Volume
111,786
Avg. Volume
304,691
Market Cap
$222.90M
Beta (5Y Monthly)
0.47
PE Ratio (TTM)
--
EPS (TTM)
-$0.48
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$11.00

Profile: TriSalus Life Sciences, Inc.

Sector
Healthcare
Industry
Medical - Devices
Full-time employees
102
CEO
Mary T. Szela

TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate -$0.14 · Revenue est. $14.02M
DateEst.Actual
Aug 6, 2026-$0.16-$0.16Miss
May 12, 2026-$0.16-$0.33Miss
Mar 5, 2026-$0.13-$0.21Miss
Nov 13, 2025-$0.17-$0.96Miss
Aug 12, 2025-$0.22-$0.27Miss
May 15, 2025-$0.20-$0.33Miss

Analyst view

Consensus price target
$11.00 ▲ +203.9%
Range $8.00 – $12.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on TLSI and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.